Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-03-01
2005-03-01
Smith, Lynette R. F. (Department: 1645)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S312000, C514S311000, C514S546000, C514S419000, C514S450000, C514S235800, C514S227500, C514S514000, C514S229800, C514S418000, C435S007400, C435S015000, C424S094100
Reexamination Certificate
active
06861442
ABSTRACT:
The present invention relates generally to the fields of immunology and medicine, and more specifically to the field of cellular signal transduction. The present invention relates, inter alia, to methods for diagnosis, treatment, and identification of therapeutics for particular inflammation-related diseases or disorders characterized by an interaction between a PYK2 polypeptide and a natural binding partner.
REFERENCES:
patent: 3691016 (1972-09-01), Patel
patent: 3969287 (1976-07-01), Jaworek et al.
patent: 4195128 (1980-03-01), Hildebrand et al.
patent: 4215051 (1980-07-01), Schroeder et al.
patent: 4229537 (1980-10-01), Hodgins et al.
patent: 4247642 (1981-01-01), Hirohara et al.
patent: 4330440 (1982-05-01), Ayers et al.
patent: 4343940 (1982-08-01), Kreighbaum et al.
patent: 4376110 (1983-03-01), David et al.
patent: 4444752 (1984-04-01), Prudden
patent: 4447608 (1984-05-01), Jones et al.
patent: 4757072 (1988-07-01), Kabbe et al.
patent: 4945050 (1990-07-01), Sanford et al.
patent: 4946778 (1990-08-01), Ladner et al.
patent: 5084462 (1992-01-01), Ackerman et al.
patent: 5242932 (1993-09-01), Gandy et al.
patent: 5296353 (1994-03-01), Ochoa et al.
patent: 5316553 (1994-05-01), Kaul et al.
patent: 5580882 (1996-12-01), Abramsky et al.
patent: 5714493 (1998-02-01), Myers et al.
patent: 5731343 (1998-03-01), Feng et al.
patent: 5804396 (1998-09-01), Plowman
patent: 5834504 (1998-11-01), Tang et al.
patent: 5837524 (1998-11-01), Schlessinger et al.
patent: 5837815 (1998-11-01), Lev et al.
patent: 5849742 (1998-12-01), App et al.
patent: 5854285 (1998-12-01), Sriram et al.
patent: 5856331 (1999-01-01), Bursten et al.
patent: 5880141 (1999-03-01), Tang et al.
patent: 5932573 (1999-08-01), Yuen
patent: 5972598 (1999-10-01), Chaudhary et al.
patent: 5981523 (1999-11-01), Panetta et al.
patent: 5985926 (1999-11-01), Leung et al.
patent: 6015812 (2000-01-01), Ferrari et al.
patent: 6077851 (2000-06-01), Bjork et al.
patent: 6114371 (2000-09-01), Tang et al.
patent: 6121287 (2000-09-01), Bjork et al.
patent: 6143764 (2000-11-01), Kubo et al.
patent: 6147106 (2000-11-01), Tang et al.
patent: 6214873 (2001-04-01), Adachi et al.
patent: 6235769 (2001-05-01), Clary
patent: 516297 (1992-12-01), None
patent: 0 520 722 (1992-12-01), None
patent: 0 562 734 (1993-09-01), None
patent: 2202145 (1988-09-01), None
patent: WO 9309236 (1993-05-01), None
patent: WO 9323569 (1993-11-01), None
patent: WO 9618738 (1996-06-01), None
patent: 9618738 (1996-06-01), None
patent: WO 9622976 (1996-08-01), None
patent: 9622976 (1996-08-01), None
patent: WO 9640116 (1996-12-01), None
patent: WO 9816639 (1998-04-01), None
patent: WO 9826054 (1998-06-01), None
patent: WO 9835056 (1998-08-01), None
Nasonova, VA et al, Ter Arkh, vol. 54(6), 1982, pp. 12-19, Russian document translated into English, Mixed Connective Tissue Disease.*
Yoneda, T et al, Cancer Research, vol. 51(16), pp. 4430-4435, 1991.*
Maguire, MP et al, J. Med. Chem. vol,. 37, pp. 2129-2137, 1994*
Current Drugs Ltd, ISSN 0962-2594, Current Opinion in Therapeutic Patents, Mar./Apr. 1993, Patent evaluation of EP-520722-A, pp. 425-427.*
Nasonova, VA et al, Ter Arkh, vol. 54(6), pp. 12-19, 1982, Mixed Connective tissue disease (abstract, English, only).*
Donovan, Frances M, Ph..D., Thrombin-induced protection and apoptossi in astrocytes and neurons:signal transduction pathways and regulation by protease nexin-1.vol. 58(08-B), Dissertation abstracts International, p. 4072, 1997, abstract only.*
Lopez-Talavera, J.C. et al, Journal of Clinical Investigation, vol. 100(3), pp. 664-670, Aug. 1997.*
Levitzki, A, FASEB journal, vol. 6(14), pp. 3275-3282, Societies for Experimental Biology, Nov. 1992.*
Glaser, KB et al, Biochemical pharmacology, Feb. 9, 1993, vol. 45(3), pp. 711-721.*
Surwit, Richard S. et al, Arch. Dermatol., vol. 120(3), pp. 329-331. Double blind study of prazosin in the treatment of Raynaud's phenomenon in scleroderma.*
Aaronson “Growth Factors and Cancer,”Science, 254:1146-1153 (1991).
Abe et al. “Molecular Characterization of a Novel Metabotropic Glutamate Receptor mGluR5 Coupled to Inositol Pohosphate/Ca2+Signal,”J. Biol. Chem., 267(19):13361-13368 (1992), © The American Society for Biochemistry and Molecular Biology, Inc., USA.
Adelman et al. “In Vitro Deletional Mutagenesis for Bacterial Production of the 20,000-Dalton Form of Human Pituitary Growth Hormone,”DNA, 2(3):183-193 (1983), Mary Ann Liebert, Inc., Publishers.
Allen et al. “Modulation of CD4 by suramin”Clin. Exp. Immunol., 91:141-146 (1991).
Anafi et al. “Tyrphostin-Induced Inhibition of p210bcr-abl Tyrosine Kinase Activity Induces K562 to Differentiate,”Blood, 82(12):3524-3529, Dec. 15, 1993, © The American Society of Hematology, USA.
Andrade et al. “A G Protein Couples Serotonin and GABABReceptors to the Same Channels in Hippocampus,”Science, 234:1261-1265 (1986).
Anouti et al. “Tremor Disorders: Diagnosis and Management”Western J. Medicine, 162(6):510-513 Jun. 1995.
Aronheim et al. “Membrane Targeting of the Nucleotide Exchange Factor Sos is Sufficient for Activating the Ras Signaling Pathway,”Cell, 78:949-961, Sep. 23, 1994, © Cell Press.
Botstein et al. “Making Mutations in vitro and Putting Them Back into Yeast,”Miami Winter Symposia—From Gene to Protein: Translation into Biotechnology, eds. Ahmad et al.,Academic Press, 19 265-274 (1982), © Academic Press.
Bowie et al. “Deciphering The Message in Protein Sequences: Tolerance to Amino Acid Substitutions,”Science, 247:1306-1310, Mar. 16, 1990.
Brinster et al. “Factors Affecting the Efficiency of Introducing Foreign DNA into Mice by Microinjecting Eggs,”Proc. Natl. Acad. Sci. USA, 82:4438-4442, Jul. 1985.
Broach “The Yeast Plasmid 2μ Circle,”Cell, 28:203-204, Feb. 1982, © MIT.
Broach “The Yeast Plasmid 2μ Circle,” inThe Molecular Biology of the Yeast Saccharomyces: Life Cycle and Inheritance, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 445-470 (1981).
Brown et al. “Ionic Channels and Their Regulation by G Protein Subunits,”Ann. Rev. Physiol., 52:197-213 (1990), © Annual Reviews Inc.
Brunton et al. “Anti-Tumour Activity of Novel Tryphostins in Breast Cancer Cells.”Proceedings of the Am. Assoc. for Cancer Res., 33:558 (#3335), Mar. 1992.
Bryckaert et al. “Inhibition of Platelet-Derived Growth Factor-Induced Mitogenesis and Tyrosine Kinase Activity in Cultured Bone Marrow Fibroblasts by Tyrphostins,”Exp. Cell Research, 199:255-261 (1992), © Academic Press, Inc.
Bullock et al. (Eds.)Techniques in Immunocytochemistry, vols. 1, 2 and 3; Table Of Contents Only, © Academic Press, Inc.
Burgess et al. “Possible dissociation of the Heparin-Binding and Mitogenic Activities of Heparin-Binding (Acidic Fibroblast) Growth Factor-1 From Its Receptor-Binding Activities By Site-Directed Mutagenesis of A Single Lysine Residue,”J. Cell Biol., 11:2129-2138 (1990), © The Rockefeller University Press.
Burke et al. “Arylamides of Hydroxylated Isoquinolines As Protein-Tyrosine Kinase Inhibitors”Bioorganic&Medicinal Chemistry Letters, 2(12):1771-1774 (1992), © Pergamon Press Ltd., Great Britain.
Burke et al. Bicyclic Compounds as Ring-Constrained Inhibitors of Protein-Tyrosine Kinase p56lckJ. of Medicinal Chemistry, 36(4):425-432, Feb. 19, 1983, © American Chemical Society.
Campbell “Monoclonal Antibody Technology, The Production and Characterization of Rodent and Human Hybridomas,”Laboratory Techniques in Biochemistry and MolecularBiology, (Table Of Contents Only), vol. 13, © Elsevier Science Publishers, Amsterdam, The Netherlands, 1984.
Cantrell “G proteins in Lymphocyte Signalling,”Current Opinion in Immunology, 6:380-384 (1994), © Current Biology Ltd.
Capecchi “Altering the Genome by Homologous Recombination,”Science, 244:1288-1292, Jun. 16, 1989.
Carmeliet &#x
Gishizky Mikhail
Okigaki Mitsuhiko
Schlessinger Joseph
Burrous Beth A.
Foley & Lardner
New York University
Portner Ginny Allen
Smith Lynette R. F.
LandOfFree
PYK2 and inflammation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with PYK2 and inflammation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and PYK2 and inflammation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3382015